Results 81 to 90 of about 2,926,291 (344)

Survival Outcomes of Local Compared With Systemic First Treatment of Non-Small Cell Lung Cancer Brain Metastases

Frontiers in Oncology, 2021
ObjectiveThis retrospective study evaluated the survival advantage of local treatment targeted to brain metastases, relative to systemic therapy, as the first option for brain metastases of non-small cell lung cancer (NSCLC).MethodsFirst reviewed were ...
Hong-Mei Liu, Hong-Mei Liu, Chun-Liu Meng, Lu-Jun Zhao   +3 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Revised guideline 'Brain metastases':More treatment options [PDF]

, 2020
The guideline on brain metastasis from the Netherlands Society of Neurology has been updated. Important changes have been made, particularly with regard to treatment of brain metastases. Treatment of patients with brain metastases is complex and requires
Lagerwaard, Frank J., Enting, Roelien H., de Vos, Filip Y.F.L., Gijtenbeek, J. M.M., Hilkens, Nina A., Hendriks, Lizza E.L.   +5 more
core   +3 more sources

Tumor microenvironment differences between primary tumor and brain metastases

Journal of Translational Medicine, 2020
The present review aimed to discuss contemporary scientific literature involving differences between the tumor microenvironment (TME) in melanoma, lung cancer, and breast cancer in their primary site and TME in brain metastases (BM).
B. Cacho-Díaz, Donovan R. García-Botello, T. Wegman-Ostrosky, G. Reyes-Soto, E. Ortiz-Sánchez, L. Herrera-Montalvo   +5 more
semanticscholar   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives

Therapeutic Advances in Medical Oncology, 2018
Brain metastases are the most common central nervous system tumors in adults, and incidence of brain metastases is increasing due to both improved diagnostic techniques (e.g.
Nuria Kotecki, Florence Lefranc, Daniel Devriendt, Ahmad Awada   +3 more
doaj   +1 more source

Alterations of functional and structural connectivity in patients with brain metastases.

PLoS ONE, 2020
Metastases are the most prevalent tumors in the brain and are commonly associated with high morbidity and mortality. Previous studies have suggested that brain tumors can induce a loss of functional connectivity and alter the brain network architecture ...
Bo Hua, Xin Ding, Minghua Xiong, Fanyu Zhang, Yi Luo, Jurong Ding, Zhongxiang Ding   +6 more
doaj   +1 more source

Extrathoracic Metastases in Pleural Mesothelioma

JTO Clinical and Research Reports, 2023
Introduction: Guidelines recommend obtaining a computed tomography scan of the chest for the staging of pleural mesothelioma and for assessing response to treatment.
Ibiayi Dagogo-Jack, MD, Beow Y. Yeap, ScD, Mari Mino-Kenudson, MD, Subba R. Digumarthy, MD   +3 more
doaj   +1 more source

Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM).

Neuro-Oncology, 2020
A recent meeting was held on March 22, 2019, among the U.S. Food and Drug Administration (FDA), clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and potential
T. Kaufmann, M. Smits, J. Boxerman, Raymond Y Huang, D. Barboriak, M. Weller, C. Chung, C. Tsien, P. Brown, L. Shankar, E. Galanis, E. Gerstner, M. J. van den Bent, T. Burns, I. Parney, G. Dunn, P. Brastianos, N. Lin, P. Wen, B. Ellingson   +19 more
semanticscholar   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source